Healthcare Business Recap: Pfizer Advances Restless Drug, ISTA Rejects Valeant Proposal
“Significant” advantages in comparison to a placebo and pramipexole have been found in a Phase III study of the drug Lyrica in treating restless leg syndrome, according to Pfizer (NYSE:PFE). The company says more analysis of the results will come.
FDA approval for routine prophylaxis of Advate hemophilia treatment has been granted to Baxter International (NYSE:BAX) following good results from a Phase IV study.
Don’t Miss: Static Consumer Prices Signal Cooling Inflation.
Pharmasset’s (NASDAQ:VRUS) announcement that it will halt Phase 2b trials of its hepatitis drug PSI-938 prompted boons for other hepatitis-related companies today. “Laboratory abnormalities associated with liver function” were found in patients using the drug, leading to its testing discontinuance.
In an 18% fall from its close on Thursday, MELA Sciences‘ (NASDAQ:MELA) 5M share secondary placement priced at $3.25. MELA, which produces medical devices, aims to bring MelaFind—its product for identifying melanoma—to market following fundraising.